Diagnostics Pipeline: Cizzle Bio Introduces Test for Earlier Lung Cancer Detection
The CIZ1B biomarker blood-based assay has 95% sensitivity for detecting earliest stage of the cancer
The CIZ1B biomarker blood-based assay has 95% sensitivity for detecting earliest stage of the cancer
From – Diagnostic Testing & Emerging Technologies
Undeniably, much of the emerging test focus is on cancer and infectious diseases. DTET wants to showcase other novel tests entering the marketplace. What follows is…
From – Diagnostic Testing & Emerging Technologies
The combination of liquid chromatography and tandem mass spectrometry enabled the discovery of four biomarkers holding promise to become…
From – Diagnostic Testing & Emerging Technologies
One of the potential therapeutic advantages of stem cells is that they can regenerate. But, a new study, published May 11 in Nature, suggests that the longer…